Cafeity Get the app

Eating

Alcohol on a GLP-1

The labels say little about alcohol directly, but it touches almost every side effect these medicines have — and many people notice they simply want it less. Here is what the guidance and the early research actually say.

By the Cafeity teamUpdated 3 min read

The short answer

The GLP-1 labels do not forbid alcohol, but the 2025 joint nutrition advisory notes it may worsen nausea and reflux on these medicines and should be minimised.1 For people on insulin or a sulfonylurea, alcohol adds to the risk of low blood sugar. Research into GLP-1 medicines and alcohol use is early: in a 2025 trial of 48 adults with alcohol use disorder, low-dose semaglutide reduced how much people drank in a laboratory session and on drinking days, but not how many days they drank.2 No GLP-1 medicine is approved to treat alcohol use disorder.

Alcohol and side effects

Alcohol irritates the stomach, relaxes the valve that keeps acid down, and dehydrates — so it meets the commonest GLP-1 side effects head on. The joint advisory specifically notes it may worsen nausea and reflux.1 It also adds calories without protein at a time when appetite is scarce. Pancreatitis, a listed warning on every GLP-1 label, has heavy drinking among its well-known causes; severe stomach pain that will not go away after drinking needs urgent care.3

Low blood sugar

The labels warn that people taking insulin or a sulfonylurea have a higher risk of low blood sugar on a GLP-1.43 Alcohol, especially on an empty stomach, can lower blood sugar further. If you take diabetes medicines, ask your prescriber about alcohol specifically.

Do GLP-1 medicines reduce alcohol cravings?

Many people report wanting to drink less, and researchers are testing whether that holds up. The best-controlled evidence so far is small. In a 2025 randomised trial, 48 adults with alcohol use disorder took low-dose semaglutide or placebo for nine weeks. Semaglutide reduced the amount of alcohol drunk in a laboratory drinking session and the number of drinks on drinking days, but did not change the number of drinking days or average drinks per day overall.2

That is a promising signal, not a treatment. No GLP-1 medicine is approved for alcohol use disorder, and anyone worried about their drinking should talk to a doctor about treatments that are.

If you do drink

  • Eat first, and keep portions small.
  • Alternate with water.
  • Expect less tolerance of the effects on your stomach, particularly after a dose increase.
  • Avoid it on days with significant nausea, vomiting or diarrhoea.

When to contact your prescriber

Keeping a record of it

A note that you had a drink sits on the same timeline as your symptoms in Cafeity, so you can see whether the next day's nausea or reflux follows it.

Cafeity "Your week, understood" screen: Ora explains that everything is calculated from your own log, offers questions such as "When are my symptoms worst?", and shows the week's protein, energy, water, weight trend, symptom days and a note that protein was 80 g under target.
Patterns from your own log.
Cafeity calories and macros screen: 284 of 2,550 kcal, protein 71 of 170 g, carbohydrate and fat, with steps and a how-you-feel mood check-in below.
The day's food and drink.

Download Cafeity on the App Store

Common questions

Can you drink alcohol on a GLP-1?
The labels do not forbid it, but the 2025 joint advisory notes it may worsen nausea and reflux and should be minimised.1 Ask your prescriber, particularly if you take diabetes medicines.
Does semaglutide reduce alcohol cravings?
A small 2025 trial in people with alcohol use disorder found reduced drinking in some measures but not others.2 It is not an approved treatment for alcohol use disorder.

Sources

  1. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society Mozaffarian D et al. 2025 (published in four journals)
  2. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial Hendershot CS et al. JAMA Psychiatry 2025;82(4):395–405
  3. Tirzepatide injection for weight management and obstructive sleep apnoea — US prescribing information DailyMed, US National Library of Medicine, version published 2 September 2026
  4. Semaglutide injection and tablets for weight management — US prescribing information DailyMed, US National Library of Medicine, version published 30 June 2026

Written by the Cafeity team from the sources listed here. Figures from prescribing information are quoted as the label states them; trial results are averages from those trials, not predictions for any one person. This page has not yet been reviewed by a clinician — see the editorial policy for how pages are researched and corrected.